<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="372602">
  <stage>Registered</stage>
  <submitdate>24/03/2017</submitdate>
  <approvaldate>28/03/2017</approvaldate>
  <actrnumber>ACTRN12617000453381</actrnumber>
  <trial_identification>
    <studytitle>A randomized, double-blind, placebo-controlled study of single ascending doses of PTG-300 in normal healthy male subjects</studytitle>
    <scientifictitle>A randomized, double-blind, placebo-controlled study of single ascending doses of PTG-300 in normal healthy male subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Thalassemia (beta)</healthcondition>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Cohort 1: PTG300 1mg subcutaneous injection of 0.9mL, once
Cohort 2: PTG300 3mg subcutaneous injection of 0.9mL, once
Cohort 3: PTG300 10mg subcutaneous injection of 0.9mL, once
Cohort 4 PTG300 20mg subcutaneous injection of 0.9mL, once
Cohort 5: PTG300 40mg subcutaneous injection of 0.9mL, once
Cohort 6: PTG300 80mg subcutaneous injection of 0.9mL, once
Cohort 7: 2 x PTG300 40mg subcutaneous injections of 0.9mL, one week apart</interventions>
    <comparator>Placebo: 0.9% NaCl solution administered as subcutaneous injection of 0.9mL, once or twice</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability will be assessed using vital signs, clinical safety labs, ECGs, physical exams and adverse events.</outcome>
      <timepoint>C1 - C6:  Daily in-patient monitoring for 7 days following first dose plus follow up visit on Day 14
C7:  Daily in-patient monitoring for 7 days following first dose and 12 days following second dose</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma and urine pharmacokinetics of PTG300, including AUC, Tmax, Cmax, T1/2</outcome>
      <timepoint>C1 - C6:  Plasma: At 1, 2, 4, 8, 24, 48, 72, 96, 120 and 168 hours post dose Urine: pooled over 24 hours post-dose

C7:  Plasma: At 2, 8, 24, 48, 72, 96, 120 and 144 hours post first dose and At 2, 8, 24, 48, 72, 96, 120, 144, 168, 192 hours post second dose.  Urine: pooled over 24 hours post each dose
</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effects of PTG300 on measures of iron in plasma (serum Fe, ferritin, transferrin)</outcome>
      <timepoint>C1 - C6:  At 1, 4, 8, 24, 48, 72, 96, 120 and 168 hours, and 14 days, post dose

C7:  At 2 and 8 hours post each dose, and every 24 hours from Day 1 to Day 21</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy male volunteers aged 18-60.
Good general health,
Body weight at least 50 kg and Body Mass Index between 18 and 30 kg/m2.
No clinically significant laboratory values
Non-smokers</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Iron supplementation or history of iron deficiency anaemia
History of significant abnormalities or diseases
Clinical significant laboratory, vital sign or ECG abnormalities
Mentally or legally incapacitated
History of substance abuse
Inability to comply with the requirements of the study protocol </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures>Review of data by cohort before decision to progress to the next cohort</designfeatures>
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>21/05/2017</anticipatedstartdate>
    <actualstartdate>22/05/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>62</samplesize>
    <actualsamplesize />
    <currentsamplesize>50</currentsamplesize>
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Protagonist Therapeutics, Inc.</primarysponsorname>
    <primarysponsoraddress>7707 Gateway Blvd., Suite 140
Newark, CA 94560
</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Protagonist Therapeutics, Inc.</fundingname>
      <fundingaddress>7707 Gateway Blvd., Suite 140
Newark, CA 94560
</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Clinical Network Services (CNS) Pty Ltd</sponsorname>
      <sponsoraddress>88 Jephson Street
Toowong
QLD 4066</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is to assess the safety and tolerability of PTG300 in normal healthy volunteers.
This includes vital signs, safety labs and physical examinations

Study drug (a single dose of either PTG-300 or placebo, or two doses a week apart) will be given as a subcutaneous injection.

The study will also evaluate the PK of the drug after dose administration, and effects of PTG300 on iron levels.

Participants will be entered into standard study cohorts of 10, 8 active:2 placebo for Cohorts 1 to 6, and 6 (5 active: 1 placebo) for Cohort 7</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Research Ethic Committee</ethicname>
      <ethicaddress>The Alfred Hospital
55 Commercial Rd
Melbourne
VIC 3004</ethicaddress>
      <ethicapprovaldate>11/05/2017</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>20/03/2017</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Jason Lickliter</name>
      <address>Nucleus Network Ltd
5th Floor, Burnet Tower, AMREP Precinct
89 Commercial Road
Melbourne, Victoria, 3004</address>
      <phone>+61 3 9076 8960</phone>
      <fax />
      <email>J.Lickliter@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Lucio Tozzi</name>
      <address>Protagonist Therapeutics, Inc.  7707 Gateway Blvd., Suite 140, Newark, CA 94560 </address>
      <phone>+1 510 474 0899</phone>
      <fax />
      <email>l.tozzi@ptgx-inc.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Lucio Tozzi</name>
      <address>Protagonist Therapeutics, Inc.  7707 Gateway Blvd., Suite 140, Newark, CA 94560 </address>
      <phone>+1 510 474 0899</phone>
      <fax />
      <email>l.tozzi@ptgx-inc.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>